Related Experiment Video
Updated: Mar 17, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
GAS5 Long Noncoding RNA Regulates CD20 Expression and Rituximab Response
Mahbubeh Rojhannezhad1, Zahra Abedi Kichi1,2, Abbas Nikravesh3
1Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Purpose:
Rituximab is the primary treatment for non-Hodgkin lymphoma (NHL), one of the most common cancers globally. One of the main challenges associated with rituximab therapy is the decline in its effectiveness over time. Several suggested potential reasons for this therapeutic resistance exist, including the downregulation of CD20 expression. Recently, the focus has shifted to long non-coding RNAs (lncRNAs) like growth arrest specific 5 (GAS5) for their involvement in various physiological functions and their potential role in the response rate to anticancer drugs. In this study, we aimed to investigate the regulatory effect of GAS5 on CD20 expression and the response of cancer cells to rituximab.
Methods:
Using the Raji cell model, we assessed the impact of GAS5 knockdown on CD20 expression and the response to rituximab through RT-qPCR assay. Western blot analysis, caspase-3 activity, and ROS assay were conducted to evaluate protein expression levels, apoptosis, and oxidative stress, respectively.
Results:
In silico analysis predicted interactions between GAS5 and regulatory proteins associated with CD20. GAS5 knockdown increased CD20 and STAT3 expression while decreasing SMAD2 levels and apoptosis. It also reduced generation of reactive oxygen species (ROS) and enhanced autophagy. However, combining GAS5 knockdown with rituximab elevated apoptosis and autophagy while further reducing ROS. These findings suggest an indirect regulatory role for GAS5 in CD20 expression, potentially via modulation of CD20-associated regulatory proteins. Nonetheless, the study has limitations, including reliance on a single cell line and the assessment of direct apoptosis only.
Conclusion:
These findings highlight a complex interplay between GAS5, CD20, rituximab, and cellular pathways, underscoring the significance of understanding these interactions to enhance cancer therapy outcomes.
Insights
Growth arrest specific 5 (GAS5) long non-coding RNA influences rituximab effectiveness in non-Hodgkin lymphoma by indirectly regulating CD20 expression. Modulating GAS5 enhances rituximab
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Rituximab is a key therapy for non-Hodgkin lymphoma (NHL).
- Therapeutic resistance to rituximab, often due to CD20 downregulation, limits its effectiveness.
- Long non-coding RNAs (lncRNAs), such as GAS5, are implicated in cancer drug response.
Purpose of the Study:
- To investigate the regulatory role of GAS5 on CD20 expression.
- To determine GAS5's effect on cancer cell response to rituximab.
Main Methods:
- Utilized the Raji cell model for experiments.
- Assessed GAS5 knockdown effects on CD20 expression via RT-qPCR.
- Evaluated protein expression, apoptosis, and oxidative stress using Western blot, caspase-3 activity, and ROS assays.
Main Results:
- GAS5 knockdown altered CD20, STAT3, and SMAD2 expression, impacting apoptosis and autophagy.
- GAS5 knockdown reduced reactive oxygen species (ROS) generation.
- Combined GAS5 knockdown and rituximab treatment increased apoptosis and autophagy while decreasing ROS.
Conclusions:
- GAS5 appears to indirectly regulate CD20 expression through associated proteins.
- Understanding the GAS5-CD20 interaction is crucial for improving rituximab efficacy in NHL.
- Further research is needed to explore these complex interactions in cancer therapy.
